CARA THERAPEUTICS INC. - COMMON STOCK

Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

01 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

25 Feb 2022 07:15:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

22 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

18 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients

10 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

20 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

18 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at Upcoming Investor Conferences

09 Nov 2021 16:30:00 By Nasdaq GlobeNewswire

Cara Therapeutics Reports Third Quarter 2021 Financial Results

08 Nov 2021 16:01:03 By Nasdaq GlobeNewswire

Cara Therapeutics Announces CEO Transition

03 Nov 2021 08:00:03 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

01 Nov 2021 16:15:00 By Nasdaq GlobeNewswire

Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

04 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

29 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference

24 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

23 Aug 2021 15:41:29 By Nasdaq GlobeNewswire

Cara Therapeutics Reports Second Quarter 2021 Financial Results

09 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

02 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the Jefferies Healthcare Conference

25 May 2021 07:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Reports First Quarter 2021 Financial Results

10 May 2021 16:01:00 By Nasdaq GlobeNewswire